Strategy Of A Corporate Split: An Interview With Mallinckrodt’s Mark Trudeau and Matt Harbaugh
Executive Summary
CEO-designate and CFO for the Mallinckrodt specialty pharma spin-out from Covidien discuss the strategy for differentiating its products in a competitive analgesic space. Despite a goal of becoming a leading specialty pharma, the new company does not plan to divest its imaging or active pharmaceutical ingredient businesses.
You may also be interested in...
FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics
Supporters of narrowing opioid drugs’ non-cancer pain indication tell FDA that pain patients often suffer the consequences of addiction and misuse.
Covidien’s Mallinckrodt To Buy CNS Therapeutics For $100M
Covidien’s pharmaceutical arm Mallinckrodt has announced its plans to acquire St. Paul, MN-based CNS Therapeutics for $100 million. The acquisition will complement Mallinckrodt’s own generic pain therapeutic offerings. Mallinckrodt is on track to be spun out of Covidien in mid-2013.
QUOTED. 27 January 2021. Scott Whitaker.
Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: